Protocol Ledger

NCT06750094 · Phase III · RECRUITING

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Interventional Phase III clinical trial protocol NCT06750094 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-12 Enrollment: 700 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06750094
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)700 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06750094
Protocol FieldVerified Registry Value
NCT IdentifierNCT06750094
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment700 participants (ESTIMATED)
Registered Start Date2024-12-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06750094
Hospital Research SiteLocationSite Profile
Banner MD Anderson Cancer CenterGilbert, AZOpen Hospital Dossier ->
Cancer and Blood Specialty ClinicLos Alamitos, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI